The University of California Los Angeles Jonsson Comprehensive Cancer Center (JCCC) is an NCI-designed matrix center conducting a wide range of inter-disciplinary research in the areas of laboratory, clinical and population sciences integrating the activities of 227 members. Its goals are to: (1) translate basic research to reduce cancer incidence, morbidity and mortality, and to improve prevention, detection, diagnosis and treatment;(2) serve as a community resource to sponsor and conduct informational activities for lay people and health care professionals and to implement outreach programs linking the communities to the research and services of JCCC;(3) provide the highest quality of clinical care by promoting multidisciplinary diagnostic, treatment, survivorship and prevention services. Over the past funding cycle 45% of patients enrolled in clinical trials were enrolled in Institutional studies. The total funding base for the JCCC is $189 million with $40.7 million in NCI funding. In addition, of 3,744 total publications in the reporting period 32% were published in high-impact journals, 40% were interprogrammatic and 25% were intraprogrammatic. Continuing support is requested for the following 11 Programs and 9 Shared Resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016042-34S1
Application #
7914837
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1996-12-01
Project End
2013-11-30
Budget Start
2009-04-02
Budget End
2009-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$500,000
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Lisova, Ksenia; Sergeev, Maxim; Evans-Axelsson, Susan et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36-44
Chang, Yu-Ling; Rossetti, Maura; Vlamakis, Hera et al. (2018) A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol :
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146
Waters, Lynnea R; Ahsan, Fasih M; Wolf, Dane M et al. (2018) Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience 5:99-109
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25

Showing the most recent 10 out of 767 publications